Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hepatitis B virus (HBV) infection, met its primary efficacy endpoint. The data show that Viread is non-inferior to the company's once-daily antiviral drug Hepsera(R) (adefovir dipivoxil) among patients with "e" antigen (HBeAg)-positive chronic hepatitis B. The primary efficacy endpoint, the proportion of patients with a complete response at week 48, was defined by serum HBV DNA levels below 400 copies/mL and histologic improvement characterized by at least a two point reduction in the Knodell necroinflammatory score (a measure of necro-inflammation - an inflammatory process in the liver including or leading to death of liver cells) with no concurrent worsening of fibrosis (scarring of liver tissue).

At 48 weeks, 66.5 percent of patients in the Viread arm (n=176) had a complete response compared to 12.2 percent in the Hepsera arm (n=90; p less than 0.001). The most commonly observed treatment-emergent adverse events of moderate intensity or higher were abdominal pain, back pain, headache, respiratory infections and transaminase elevations. The incidence of these events was comparable between the Viread and Hepsera arms of the study. In addition, the most frequently observed grade 3 or 4 laboratory abnormalities were elevations in transaminase and serum amylase and were comparable between the two arms. Full study results will be submitted for presentation at an upcoming scientific meeting.

Study 103 is the second of two Phase III pivotal studies evaluating the efficacy, safety and tolerability of Viread for the treatment of chronic hepatitis B to have met its primary efficacy endpoint. Earlier this month,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014 MiMedx Group, ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic ... Tom Koob , Ph.D., Chief Scientific Officer, will present ... Koob will present on Tuesday, October 7, 2014, at ...
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... Reportlinker.com announces that a new market research ... Neurostimulation Devices - Global Pipeline ... 2016 http://www.reportlinker.com/p0285077/Neurostimulation-Devices---Global-Pipeline-Analysis--Opportunity-Assessment-and-Market-Forecasts-to-2016.html ... Pipeline Analysis, Opportunity Assessment and Market Forecasts ...
... announces that a new market research report is ... Dysfunction - Pipeline Assessment and Market Forecasts to ... Erectile Dysfunction - Pipeline Assessment and Market ... and healthcare report, "Erectile Dysfunction - Pipeline Assessment ...
Cached Medicine Technology:Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 11Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 6
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... the stops to rescue surgical patients in crisis are ... such heroism is questionable, a new study suggests. ... saving elderly patients with life-threatening complications after major surgery, ... senior author Dr. Amir Ghaferi. He is assistant professor ...
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
(Date:10/1/2014)... 2014 Familylifeinsurancequotes.org has released a ... for senior citizens. , Senior citizens can qualify ... sell coverage to seniors who are over 50 years ... without taking a medical examination. , Term life insurance ... senior clients can qualify. Having life insurance during retirement ...
(Date:10/1/2014)... 01, 2014 Lifeinsurance-policy.com has released ... best life insurance prices for smokers. , Smoking will ... premiums. Comparing quotes is the best method to find ... for customers who need coverage. , Whole life ... of the policy. Since the coverage is permanent, the ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2
... to Integrate with MEDITECH MAGIC Health Information System via ... Information Management , , ... STRM ) today announced that it will ... MEDITECH MAGIC Health Information System of Massena Memorial Hospital, ...
... Dec. 9 Frost & Sullivan, a global ... recently held Manufacturing Summit, hosted the India Manufacturing ... Bangalore. Instituted in 2004, the awards aim to ... manufacturing capabilities and acknowledge the best facilities in ...
... the recent economic downturn, natural health degree ... still experiencing a wellness boom, as holistic ... the Internet,s top natural health career site ... training, chiropractic, nutrition, Reiki and reflexology career ...
... spend weeks in recovery after cosmetic skin treatments can often return ... thanks to an innovative new tool. The Pixel CO2 OMNIFIT device ... three. The technology is among the latest treatment tools available to ... ...
... Roche Molecular Diagnostics,announced today that it has received ... TaqMan(R) HBV Test v2.0, allowing it to be sold,for ... sensitive test offers,Roche,s fully automated real-time PCR technology to ... hepatitis B virus (HBV) DNA in patient,plasma and serum. ...
... Duane Reade Holdings, Inc. today announced the appointment of Mr. ... effective December 1, 2008. Mr. Scorpiniti reports directly to ... adds value and expertise to Duane Reade,s capable management team ... senior executives. , , ...
Cached Medicine News:Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 2Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 3Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 4Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 5Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 2Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 3Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 4Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 5Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 3Health News:Juva Skin Center's Laser Skin Treatments Take an Innovative Leap with Pixel CO2 Device 2Health News:Improved Testing for Hepatitis B Virus From Roche 2Health News:Improved Testing for Hepatitis B Virus From Roche 3Health News:Duane Reade Holdings, Inc. Further Strengthens Management Team With Addition of Frank Scorpiniti, SVP, Pharmacy Operations 2Health News:Duane Reade Holdings, Inc. Further Strengthens Management Team With Addition of Frank Scorpiniti, SVP, Pharmacy Operations 3
... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the quantitative determination of alkaline phosphatase in human serum....
Medicine Products: